Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease?

Michelle M Mielke, Norman J. Haughey

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Understanding the etiopathological processes of Alzheimer's disease (AD) in the preclinical and early clinical stages will be important in developing new therapeutic targets and biomarkers. There is growing consensus that nonamyloid targets will be necessary to reverse or slow AD progression. Lipidomic, metabolomic and targeted approaches have identified pathways and products of sphingolipid metabolism that are altered early in the course of AD and contribute to the neuropathological alterations associated with AD, including amyloid-β production, tau formation and neurodegeneration. In this article, we briefly review the current literature on the role of sphingolipids in the underlying pathophysiology of AD, and then discuss the current state of translating these findings to clinical populations and the potential utility of plasma sphingolipids as diagnostic and/or prognostic indicators of AD.

Original languageEnglish (US)
Pages (from-to)525-536
Number of pages12
JournalClinical Lipidology
Volume7
Issue number5
DOIs
StatePublished - Oct 2012

Fingerprint

Sphingolipids
Alzheimer Disease
Biomarkers
Metabolomics
Amyloid
Disease Progression
Consensus
Population

Keywords

  • Alzheimer's disease
  • amyloid
  • biomarker
  • blood
  • ceramide
  • lipid
  • neurodegeneration
  • sphingolipid
  • tau

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease? / Mielke, Michelle M; Haughey, Norman J.

In: Clinical Lipidology, Vol. 7, No. 5, 10.2012, p. 525-536.

Research output: Contribution to journalArticle

@article{66e7419c8c254f14b32c52aae3c7fe56,
title = "Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease?",
abstract = "Understanding the etiopathological processes of Alzheimer's disease (AD) in the preclinical and early clinical stages will be important in developing new therapeutic targets and biomarkers. There is growing consensus that nonamyloid targets will be necessary to reverse or slow AD progression. Lipidomic, metabolomic and targeted approaches have identified pathways and products of sphingolipid metabolism that are altered early in the course of AD and contribute to the neuropathological alterations associated with AD, including amyloid-β production, tau formation and neurodegeneration. In this article, we briefly review the current literature on the role of sphingolipids in the underlying pathophysiology of AD, and then discuss the current state of translating these findings to clinical populations and the potential utility of plasma sphingolipids as diagnostic and/or prognostic indicators of AD.",
keywords = "Alzheimer's disease, amyloid, biomarker, blood, ceramide, lipid, neurodegeneration, sphingolipid, tau",
author = "Mielke, {Michelle M} and Haughey, {Norman J.}",
year = "2012",
month = "10",
doi = "10.2217/clp.12.59",
language = "English (US)",
volume = "7",
pages = "525--536",
journal = "Future Lipidology",
issn = "1746-0875",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease?

AU - Mielke, Michelle M

AU - Haughey, Norman J.

PY - 2012/10

Y1 - 2012/10

N2 - Understanding the etiopathological processes of Alzheimer's disease (AD) in the preclinical and early clinical stages will be important in developing new therapeutic targets and biomarkers. There is growing consensus that nonamyloid targets will be necessary to reverse or slow AD progression. Lipidomic, metabolomic and targeted approaches have identified pathways and products of sphingolipid metabolism that are altered early in the course of AD and contribute to the neuropathological alterations associated with AD, including amyloid-β production, tau formation and neurodegeneration. In this article, we briefly review the current literature on the role of sphingolipids in the underlying pathophysiology of AD, and then discuss the current state of translating these findings to clinical populations and the potential utility of plasma sphingolipids as diagnostic and/or prognostic indicators of AD.

AB - Understanding the etiopathological processes of Alzheimer's disease (AD) in the preclinical and early clinical stages will be important in developing new therapeutic targets and biomarkers. There is growing consensus that nonamyloid targets will be necessary to reverse or slow AD progression. Lipidomic, metabolomic and targeted approaches have identified pathways and products of sphingolipid metabolism that are altered early in the course of AD and contribute to the neuropathological alterations associated with AD, including amyloid-β production, tau formation and neurodegeneration. In this article, we briefly review the current literature on the role of sphingolipids in the underlying pathophysiology of AD, and then discuss the current state of translating these findings to clinical populations and the potential utility of plasma sphingolipids as diagnostic and/or prognostic indicators of AD.

KW - Alzheimer's disease

KW - amyloid

KW - biomarker

KW - blood

KW - ceramide

KW - lipid

KW - neurodegeneration

KW - sphingolipid

KW - tau

UR - http://www.scopus.com/inward/record.url?scp=84869452365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869452365&partnerID=8YFLogxK

U2 - 10.2217/clp.12.59

DO - 10.2217/clp.12.59

M3 - Article

AN - SCOPUS:84869452365

VL - 7

SP - 525

EP - 536

JO - Future Lipidology

JF - Future Lipidology

SN - 1746-0875

IS - 5

ER -